4 Biotech Cos. Raise $476M In Cooley, Davis Polk-Led IPOs
A quartet of biotechnology and biopharmaceutical companies focused on treating cancer, solid tumors and neurodegenerative and metabolic disorders began trading on Thursday after pricing initial public offerings that raised a combined...To view the full article, register now.
Already a subscriber? Click here to view full article